Companies › Vicore Pharma
1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Buloxibutid Angiotensin II type 2 receptor agonist | AGTR2 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06588686 | Buloxibutid | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | May 2027 |
–
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D SpliSense ReCode Therapeutics Anagram Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.